Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium

T M Beer; D C Smith; A Hussain; M Alonso; J Wang; M Giurescu; K Roth; Y Wang

doi:10.1038/bjc.2012.339

Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium

British Journal of Cancer ◽

10.1038/bjc.2012.339 ◽

2012 ◽

Vol 107 (5) ◽

pp. 808-813 ◽

Cited By ~ 14

Author(s):

T M Beer ◽

D C Smith ◽

A Hussain ◽

M Alonso ◽

J Wang ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Trials ◽

Phase Ii ◽

Department Of Defense ◽

Phase Ii Study ◽

Cancer Clinical Trials ◽

Castration Resistant Prostate Cancer ◽

First Line ◽

Castration Resistant

Download Full-text

Bone scan “flare” in patients receiving abiraterone acetate (AA) for metastatic castration resistant prostate cancer (mCRPC): Analysis of data from a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.4545 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 4545-4545 ◽

Cited By ~ 1

Author(s):

S. K. Shah ◽

C. J. Ryan ◽

C. Kilian ◽

A. Hubbell ◽

T. S. Kheoh ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Trials ◽

Phase Ii ◽

Department Of Defense ◽

Bone Scan ◽

Phase Ii Study ◽

Abiraterone Acetate ◽

Cancer Clinical Trials ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text

Activity of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with ketoconazole (keto): A prospective phase II study from the Prostate Cancer Clinical Trials Consortium.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.5039 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 5039-5039 ◽

Cited By ~ 1

Author(s):

Won Kim ◽

John Wilton ◽

Li Zhang ◽

Amy M. Lin ◽

Lawrence Fong ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Trials ◽

Phase Ii ◽

Phase Ii Study ◽

Abiraterone Acetate ◽

Cancer Clinical Trials ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Prospective Phase ◽

Previously Treated

Download Full-text

Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium

Investigational New Drugs ◽

10.1007/s10637-010-9573-5 ◽

2010 ◽

Vol 30 (2) ◽

pp. 749-757 ◽

Cited By ~ 52

Author(s):

Ajjai Alva ◽

Susan Slovin ◽

Stephanie Daignault ◽

Michael Carducci ◽

Robert DiPaola ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Trials ◽

Phase Ii ◽

Phase Ii Study ◽

Cancer Clinical Trials ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text

Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2014.12.004 ◽

2015 ◽

Vol 13 (3) ◽

pp. e191-e198 ◽

Cited By ~ 5

Author(s):

Rahul R. Aggarwal ◽

Tomasz M. Beer ◽

Vivian K. Weinberg ◽

Celestia Higano ◽

Mary-Ellen Taplin ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Trials ◽

Department Of Defense ◽

Phase Ii Trial ◽

Cancer Clinical Trials ◽

Castration Resistant Prostate Cancer ◽

Gm Csf ◽

Castration Resistant ◽

Randomized Phase Ii ◽

Intermittent Chemotherapy

Download Full-text

A phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.tps246 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS246-TPS246 ◽

Cited By ~ 2

Author(s):

U. Emmenegger ◽

S. S. Sridhar ◽

C. M. Booth ◽

R. Kerbel ◽

S. R. Berry ◽

...

Keyword(s):

Prostate Cancer ◽

Maintenance Therapy ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant Prostate Cancer ◽

First Line ◽

Castration Resistant

Download Full-text

A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195

Investigational New Drugs ◽

10.1007/s10637-015-0252-4 ◽

2015 ◽

Vol 33 (4) ◽

pp. 969-976 ◽

Cited By ~ 29

Author(s):

B. J. Eigl ◽

S. North ◽

E. Winquist ◽

D. Finch ◽

L. Wood ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Trials ◽

Phase Ii ◽

Hdac Inhibitor ◽

Phase Ii Study ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text

A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study

Prostate Cancer and Prostatic Diseases ◽

10.1038/pcan.2011.49 ◽

2011 ◽

Vol 15 (1) ◽

pp. 87-92 ◽

Cited By ~ 13

Author(s):

J E Ward ◽

T Karrison ◽

G Chatta ◽

M Hussain ◽

D Shevrin ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Trials ◽

Phase Ii ◽

Department Of Defense ◽

Phase Ii Study ◽

Cancer Clinical Trials ◽

University Of Chicago ◽

Randomized Phase Ii

Download Full-text

A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-010-1389-7 ◽

2010 ◽

Vol 67 (4) ◽

pp. 927-933 ◽

Cited By ~ 15

Author(s):

Srikala S. Sridhar ◽

Christina M. Canil ◽

Kim N. Chi ◽

Sebastien J. Hotte ◽

Scott Ernst ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Antisense Oligonucleotide ◽

Phase Ii Study ◽

Line Treatment ◽

Castration Resistant Prostate Cancer ◽

First Line ◽

Castration Resistant ◽

First Line Treatment

Download Full-text

Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium

Investigational New Drugs ◽

10.1007/s10637-010-9420-8 ◽

2010 ◽

Vol 29 (6) ◽

pp. 1432-1440 ◽

Cited By ~ 34

Author(s):

Deborah A. Bradley ◽

Stephanie Daignault ◽

Charles J. Ryan ◽

Robert S. DiPaola ◽

David C. Smith ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Trials ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Trial ◽

Cancer Clinical Trials ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Randomized Phase Ii

Download Full-text

Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the DoD Prostate Cancer Clinical Trials Consortium.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.4684 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 4684-4684

Author(s):

E. J. Small ◽

T. M. Beer ◽

V. K. Weinberg ◽

C. S. Higano ◽

L. T. Nordquist ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Trials ◽

Phase Ii ◽

Phase Ii Trial ◽

Cancer Clinical Trials ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Randomized Phase Ii ◽

Intermittent Chemotherapy

Download Full-text